I like BOT. It has already made quite a move but does remind me of a PAR-like move in progress. (PAR and OPT took off following successful Phase 2A trials last year) The drug is safe. That is a key advantage because most drugs end up curing the problem but also kill the mouse. In this case we know the safety profile and await results from a small (n=60 I believe) Phase 2A trial that is recruiting now and will have a readout in December. It targets MSDA infection in hospitals which is a major health problem with antibiotic resistance increasing. A big shout out to @bernsta for flagging this one to me. No mice die in the following video.
